Tumour-inhibiting platinum complexes--state of the art and future perspectives.

[1]  N. Farrell,et al.  Novel approaches to polynuclear platinum pro-drugs. Selective release of cytotoxic platinum-spermidine species through hydrolytic cleavage of carbamates. , 2001, Inorganic chemistry.

[2]  R. Maekawa,et al.  Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. , 2001, Cancer letters.

[3]  M. Galanski,et al.  Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5'-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry. , 2001, Journal of inorganic biochemistry.

[4]  S. Bombard,et al.  Platination of the (T2G4)4 telomeric sequence: a structural and cross-linking study. , 2001, Biochemistry.

[5]  R. Duncan,et al.  Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[6]  V. Brabec,et al.  Conformation, Recognition by High Mobility Group Domain Proteins, and Nucleotide Excision Repair of DNA Intrastrand Cross-links of Novel Antitumor Trinuclear Platinum Complex BBR3464* , 2001, The Journal of Biological Chemistry.

[7]  G. Natile,et al.  Current status of trans-platinum compounds in cancer therapy , 2001 .

[8]  C. Manzotti,et al.  In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma , 2001, Cancer Chemotherapy and Pharmacology.

[9]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[10]  E. Gamelin,et al.  A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. , 2001, Journal of neurophysiology.

[11]  C. Manzotti,et al.  The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. , 2001, European journal of cancer.

[12]  Y. Bang,et al.  A Phase I study of cis‐malonato[(4R,5R)‐4,5‐bis(aminomethyl)‐1,3‐dioxolane] platinum(II) in patients with advanced malignancies , 2001, Cancer.

[13]  M. Gore,et al.  ZD0473 phase II monotherapy trial in second-line ovarian cancer , 2001 .

[14]  U. Gatzemeier,et al.  A phase I dose-escalation study of zd0473 combined with paclitaxel in refractory solid malignancies , 2001 .

[15]  A. Boddy,et al.  A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin , 2001, British Journal of Cancer.

[16]  Y. Ueyama,et al.  Inhibition of Telomerase Activity as a Measure of Tumor Cell Killing by Cisplatin in Squamous Cell Carcinoma Cell Line , 2001, Chemotherapy.

[17]  S. Brienza,et al.  Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  G Milano,et al.  Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines , 2001, British Journal of Cancer.

[19]  N. Farrell,et al.  Kinetic analysis of the stepwise formation of a long-range DNA interstrand cross-link by a dinuclear platinum antitumor complex: evidence for aquated intermediates and formation of both kinetically and thermodynamically controlled conformers. , 2001, Journal of the American Chemical Society.

[20]  M. Galanski,et al.  Capillary electrophoretic study of carboplatin and analogues with nucleoside monophosphates, di- and trinucleotides. , 2001, Journal of inorganic biochemistry.

[21]  E. Reed,et al.  Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues. , 2000, Biochemical pharmacology.

[22]  S. Mani,et al.  Novel combinations with oxaliplatin. , 2000, Oncology.

[23]  V. Brabec,et al.  Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving groups , 2000, Journal of Biological Inorganic Chemistry.

[24]  A. Cailleux,et al.  Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[25]  E. Raymond,et al.  Oxaliplatin-induced damage of cellular DNA. , 2000, Molecular pharmacology.

[26]  R. Gust,et al.  [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring , 2000, Journal of Cancer Research and Clinical Oncology.

[27]  M. Ducreux,et al.  Oxaliplatin in colorectal cancer: an overview. , 2000, Seminars in oncology.

[28]  J. Reedijk,et al.  Reaction of DNA oligonucleotides with [Pt(dien)GSMe]2+ (GSMe =S-methylated glutathione) and cis-[Pt(NH3)2(GSMe)2]2+: evidence of oligonucleotide platination via sulfur-coordinated platinum intermediates , 2000, JBIC Journal of Biological Inorganic Chemistry.

[29]  M. Zucchetti,et al.  Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Misset,et al.  Oxaliplatin clinical activity: a review. , 2000, Critical reviews in oncology/hematology.

[31]  N. Farrell,et al.  BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  J. Kozelka,et al.  A complete kinetic study of GG versus AG plantination suggests that the doubly aquated derivatives of cisplatin are the actual DNA binding species. , 2000, Chemistry.

[33]  R. Perez-soler,et al.  Intraliposomal chemical activation patterns of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) (L-NDDP)-a potential antitumour agent. , 2000, Journal of microencapsulation.

[34]  M. Galanski,et al.  Is reduction required for antitumour activity of platinum(IV) compounds? Characterisation of a platinum(IV)–nucleotide adduct [enPt(OCOCH3)3(5′-GMP)] by NMR spectroscopy and ESI-MS , 2000 .

[35]  E. Gamelin,et al.  Clinical pharmacokinetics of oxaliplatin: a critical review. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  Calvert,et al.  An intermittent phase I and pharmacokinetic study of BBR3464, a novel cationic triplatinum complex , 2000 .

[37]  L. Kèlland.  New Platinum Drugs: The Pathway to Oral Therapy , 2000 .

[38]  N. Farrell.  Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents: Toward a New Paradigm , 2000 .

[39]  N. Farrell,et al.  Platinum-Based Drugs in Cancer Therapy , 2000, Cancer Drug Discovery and Development.

[40]  R. Chaganti,et al.  Genetics and biology of adult human male germ cell tumors. , 2000, Cancer research.

[41]  M. van Glabbeke,et al.  Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[43]  T. Hambley,et al.  Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs , 2000, British Journal of Cancer.

[44]  H. Groen,et al.  Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Bekradda,et al.  Oxaliplatin: a new therapeutic option in colorectal cancer. , 1999, Seminars in oncology.

[46]  C. O'Neill,et al.  Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. , 1999, Chemico-biological interactions.

[47]  A. Paradiso,et al.  In vitro antitumour activity and cellular pharmacological properties of the platinum-iminoether complex trans-[PtCl2[E-HN=C(OMe)Me]2]. , 1999, International journal of oncology.

[48]  S. Kato,et al.  A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers. , 1999, Internal medicine.

[49]  N. Farrell,et al.  Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. , 1999, Journal of inorganic biochemistry.

[50]  G. Natile,et al.  In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands. , 1999, Journal of inorganic biochemistry.

[51]  J. Perez,et al.  Apoptosis induction and inhibition of H-ras overexpression by novel trans-[PtCl2(isopropylamine)(amine')] complexes. , 1999, Journal of inorganic biochemistry.

[52]  Marina Ottaway,et al.  Debating Democracy Assistance: Toward a New Paradigm , 1999 .

[53]  B. Keppler,et al.  Calcium Ions Do Accelerate the DNA Binding of New Antitumor‐Active Platinum Aminophosphonate Complexes , 1999 .

[54]  J. Ahn,et al.  Phase II clinical trial of SKI‐2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma , 1999, Cancer.

[55]  N. Farrell,et al.  The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells. , 1999, Journal of inorganic biochemistry.

[56]  D. S. Kim,et al.  Phase II trial of a novel platinum analog, SKI 2053R, in patients with previously untreated extensive-stage small-cell lung cancer. , 1999, American journal of clinical oncology.

[57]  J. Perez,et al.  Preparation and characterization of novel trans-[PtCl(2)(amine)(isopropylamine)] compounds: cytotoxic activity and apoptosis induction in ras-transformed cells. , 1999, Journal of medicinal chemistry.

[58]  J. Kozelka,et al.  Kinetic aspects of interactions between DNA and platinum complexes , 1999 .

[59]  J. Reedijk.  Why does Cisplatin reach Guanine-n7 with competing s-donor ligands available in the cell? , 1999, Chemical reviews.

[60]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[61]  S. Chaney,et al.  Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. , 1999, Cancer research.

[62]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[63]  N. Farrell,et al.  A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts , 1999, British Journal of Cancer.

[64]  P. Sadler,et al.  A New Platinum Anticancer Drug Forms a Highly Stereoselective Adduct with Duplex DNA. , 1999, Angewandte Chemie.

[65]  M. Galanski,et al.  Design of Platinum Complexes with High Affinity for Osteosarcoma and Bone Metastases — Structure-Activity Relationship , 1999 .

[66]  M. Galanski,et al.  The Mode of Action of Antitumor Platinum Compounds Linked to Amino Phosphonic Acids with Particular Activity Against Bone Malignancies and the Influence of Calcium Ions onto the DNA Binding Behavior , 1999 .

[67]  R. Duncan,et al.  HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. , 1999, European journal of cancer.

[68]  G. Natile,et al.  Cytotoxicity and DNA binding mode of new platinum-iminoether derivatives with different configuration at the iminoether ligands. , 1999, Anti-cancer drug design.

[69]  A. W. Boersma,et al.  Distinct p53‐independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines , 1999, International journal of cancer.

[70]  V. Brabec,et al.  DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent. , 1999, Biochemistry.

[71]  H. Choy,et al.  Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. , 1999, International Journal of Radiation Oncology, Biology, Physics.

[72]  E. Raymond,et al.  Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  J. Essigmann,et al.  Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage. , 1999, Biochemistry.

[74]  S. Wyrick,et al.  High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[75]  R. Wood,et al.  Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours , 1999, Current Biology.

[76]  J. Reedijk,et al.  PLATINUM-THIOETHER BONDS CAN BE REVERTED BY GUANINE-N7 BONDS IN PT(DIEN)2+MODEL ADDUCTS , 1999 .

[77]  G. Bernhardt,et al.  [meso‐1,2‐Bis(2,6‐dichloro‐4‐hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a Compound with a Specific Activity on Hormone‐Sensitive Breast Cancers ‐ Evidence for a Diethylstilbestrol‐Like Mode of Action , 1999, Archiv der Pharmazie.

[78]  I. Viano,et al.  A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. , 1999, Molecular pharmacology.

[79]  J. Wang,et al.  Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells , 1999, British Journal of Cancer.

[80]  J. Emile,et al.  Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  H. Mizoguchi,et al.  Cytostatic concentrations of anticancer agents do not affect telomerase activity of leukaemic cells in vitro. , 1999, European journal of cancer.

[82]  F. Goldwasser,et al.  Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line. , 1999, Anti-cancer drugs.

[83]  C. Napier,et al.  Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. , 1998, Molecular pharmacology.

[84]  K. Sugita,et al.  Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model. , 1998, European journal of cancer.

[85]  G. Milano,et al.  Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  D. Lebwohl,et al.  Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. , 1998, European journal of cancer.

[87]  S. Cannistra,et al.  Enrichment for DNA mismatch repair‐deficient cells during treatment with cisplatin , 1998, International journal of cancer.

[88]  T. Kunkel,et al.  The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.

[89]  E. Cvitkovic.  Cumulative toxicities from cisplatin therapy and current cytoprotective measures. , 1998, Cancer treatment reviews.

[90]  F. Zunino,et al.  Sensitivity to cisplatin and platinum-containing compounds of Schizosaccharomyces pombe rad mutants. , 1998, Molecular pharmacology.

[91]  V. Brabec,et al.  DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)]. , 1998, European journal of biochemistry.

[92]  J. Armand,et al.  Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) , 1998 .

[93]  V. Reuter,et al.  Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation , 1998, Oncogene.

[94]  A. W. Boersma,et al.  Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. , 1998, British Journal of Cancer.

[95]  Sunhee Choi,et al.  Reduction and Anticancer Activity of Platinum(IV) Complexes , 1998 .

[96]  P. Sadler,et al.  Stereospecific and Kinetic Control over the Hydrolysis of a Sterically Hindered Platinum Picoline Anticancer Complex , 1998 .

[97]  S. Lippard,et al.  Telomere loss in cells treated with cisplatin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[98]  E. Raymond,et al.  Activity of oxaliplatin against human tumor colony-forming units. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[99]  M. Marty,et al.  Pharmacokinetics and safety profile of oxaliplatin. , 1998, Seminars in oncology.

[100]  S. Lippard,et al.  Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. , 1998, Biochemistry.

[101]  D. Moras,et al.  Cisplatin‐ and UV‐damaged DNA lure the basal transcription factor TFIID/TBP , 1997, The EMBO journal.

[102]  S. Lippard,et al.  Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. , 1997, Biochemistry.

[103]  A. Begg,et al.  Oral platinum analogue JM216, a radiosensitizer in oxic murine cells. , 1997, International journal of radiation biology.

[104]  A. W. Boersma,et al.  Lack of correlation between cisplatin‐induced apoptosis, p53 status and expression of Bcl‐2 family proteins in testicular germ cell tumour cell lines , 1997, International journal of cancer.

[105]  L. Kèlland,et al.  cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[106]  S. Groleau,et al.  The synthesis and characterization of new triphenylethylene platinum(II) complexes , 1997 .

[107]  E. Raymond,et al.  Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers , 1997, Anti-cancer drugs.

[108]  V. Brabec,et al.  DNA modifications by antitumor trans-[PtCl2(E-iminoether)2]. , 1997, Molecular pharmacology.

[109]  S. Duffull,et al.  Clinical Pharmacokinetics and Dose Optimisation of Carboplatin , 1997, Clinical pharmacokinetics.

[110]  I. Judson,et al.  Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  M. Poirier,et al.  Preferential formation and decreased removal of cisplatin-DNA adducts in Chinese hamster ovary cell mitochondrial DNA as compared to nuclear DNA. , 1997, Mutation research.

[112]  D. Dunlop,et al.  Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[113]  J. Robert,et al.  Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[114]  J. Double,et al.  Inhibition of telomerase activity by cisplatin in human testicular cancer cells. , 1997, European journal of cancer.

[115]  J. Masters,et al.  DNA Repair capacity and cisplatin sensitivity of human testis tumour cells , 1997, International journal of cancer.

[116]  W. Hong,et al.  Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[117]  N. Veldman,et al.  Crystal and Molecular Structures of Asymmetric cis- and trans-Platinum(II/IV) Compounds and Their Reactions with DNA Fragments , 1997 .

[118]  A. Khokhar,et al.  Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum(IV) carboxylate complexes. , 1997, Journal of medicinal chemistry.

[119]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[120]  J. Masters,et al.  DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. , 1996, Biochemical pharmacology.

[121]  P. Chollet,et al.  Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[122]  R. Rietbroek,et al.  In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. , 1996, Carcinogenesis.

[123]  C. Taylor,et al.  Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours. , 1996, British Journal of Cancer.

[124]  V. Bohr,et al.  Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. , 1996, Carcinogenesis.

[125]  E. Montgomery,et al.  Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[126]  S. Aebi,et al.  The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.

[127]  S. Lippard,et al.  Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.

[128]  J. Essigmann,et al.  The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. , 1996, Chemistry & biology.

[129]  C. Boland,et al.  Loss of DNA mismatch repair in acquired resistance to cisplatin. , 1996, Cancer research.

[130]  D. Lilley,et al.  Human MutScv recognizes damaged DNA base pairs containing 06-methylguanine, 04-methylthymine, or the cisplatin-d(GpG) adduct , 2005 .

[131]  A. Hall,et al.  Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. , 1996, European journal of cancer.

[132]  Kui Wang,et al.  The events that occur when cisplatin encounters cells , 1996 .

[133]  L. Weber,et al.  Effect of overexpression of the small heat shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. , 1996, Cancer research.

[134]  V. Gorbunova,et al.  [Cycloplatam in the treatment of patients with disseminated prostatic cancer]. , 1996, Urologiia i nefrologiia.

[135]  C. Chresta,et al.  Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. , 1996, Cancer research.

[136]  Peter J. Sadler,et al.  Ring-Opened Adducts of the Anticancer Drug Carboplatin with Sulfur Amino Acids. , 1996, Inorganic chemistry.

[137]  J. Welink,et al.  Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection. , 1996, Journal of chromatography. B, Biomedical applications.

[138]  G. Natile,et al.  Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. , 1995, Chemico-biological interactions.

[139]  Y. Zou,et al.  Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformational changes in DNA. , 1995, Biochemistry.

[140]  S. Lippard,et al.  DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. , 1995, Biochemistry.

[141]  R. Perez,et al.  Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. , 1995, Cancer letters.

[142]  S. Groleau,et al.  Synthesis and in vitro biological evaluation of new triphenylethylene platinum (II) complexes , 1995 .

[143]  P. Sadler,et al.  Platination Pathways for Reactions of Cisplatin with GG Single-Stranded and Double-Stranded Decanucleotides† , 1995 .

[144]  L. Kèlland,et al.  DNA‐binding properties of novel cis‐ and trans platinum‐based anticancer agents in 2 human ovarian carcinoma cell lines , 1995, International journal of cancer.

[145]  L. Kèlland,et al.  Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[146]  L. Kèlland,et al.  Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. , 1995, Journal of medicinal chemistry.

[147]  R. Baan,et al.  Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. , 1995, Biochemistry.

[148]  M. Osmak,et al.  Modulation of resistance to cisplatin by amphotericin B and aphidicolin in human larynx carcinoma cells , 1995, Cancer Chemotherapy and Pharmacology.

[149]  R. Freedman,et al.  A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer. , 1995, Gynecologic oncology.

[150]  M. K. Clements,et al.  Polymerase chain reaction analysis of cisplatin-induced mitochondrial DNA damage in human ovarian carcinoma cells. , 1995, Anti-cancer drugs.

[151]  A. Cats,et al.  Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer. , 1995, British Journal of Cancer.

[152]  M. Poirier,et al.  Preferential binding of cisplatin to mitochondrial DNA of Chinese hamster ovary cells. , 1995, Mutation research.

[153]  V. Brabec,et al.  DNA interactions of antitumor platinum(IV) complexes. , 1995, European journal of biochemistry.

[154]  M. Yamamoto,et al.  In vitro cytotoxicities and in vivo distribution of transferrin-platinum(II) complex. , 1995, Journal of pharmaceutical sciences.

[155]  R. Leone,et al.  Cisplatin Pharmacokinetics Using a Five‐Day Schedule During Repeated Courses of Chemotherapy in Germ Cell Tumors , 1995, Therapeutic drug monitoring.

[156]  R. Ozols,et al.  Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. , 1994, Cancer research.

[157]  G. Weiss,et al.  Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812) , 1994, Anti-cancer drugs.

[158]  A. Khokhar,et al.  Axial ligands and alicyclic ring size modulate the activity and biochemical pharmacology of ammine/cycloalkylamine-platinum(IV) complexes in tumor cells resistant to cis-diamminedichloroplatinum(II) or trans-1R,2R-1S,2S-diaminocyclohexanetetrachloroplatinum(IV). , 1994, Cancer research.

[159]  Y. Suh,et al.  General pharmacology of cis-malonato[4R,5R)-4,5-bis-(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II). , 1994, Arzneimittel-Forschung.

[160]  J. Yu,et al.  Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.

[161]  A. Hongo,et al.  A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin. , 1994, The International journal of biochemistry.

[162]  A. Khokhar,et al.  Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes , 1994, Journal of Cancer Research and Clinical Oncology.

[163]  W. Kaufmann,et al.  Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. , 1994, Cancer research.

[164]  P. Andrews,et al.  Drug accumulation and DNA platination in cells exposed to aquated cisplatin species. , 1994, Cancer letters.

[165]  B. Van Houten,et al.  Sequence specificity of DNA-DNA interstrand cross-link formation by cisplatin and dinuclear platinum complexes. , 1994, Biochemistry.

[166]  W. E. Lindup,et al.  Cisplatin nephrotoxicity: decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices. , 1994, Biochemical pharmacology.

[167]  B. Keppler,et al.  New Antitumor Platinum Compounds Linked to Amino Phosphonic Acids Which Lose the Phosphonate and Tertiary Amine Ligand upon Binding to Nucleic Acids , 1994 .

[168]  R. Ozols,et al.  Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. , 1994, Biochemical pharmacology.

[169]  H. Maki,et al.  Effect of single DNA lesions on in vitro replication with DNA polymerase III holoenzyme. Comparison with other polymerases. , 1994, Journal of molecular biology.

[170]  R. Perez-soler,et al.  Cellular accumulation and DNA damage induced by liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum+ ++(II) in LoVo and LoVo/PDD cells. , 1994, Anti-cancer drugs.

[171]  P. O'dwyer,et al.  Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. , 1994, Cancer research.

[172]  R. Perez,et al.  Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. , 1994, Cancer research.

[173]  M. Ruevekamp,et al.  Characterization of resistance mechanisms to cis-diamminedichloroplatinum(II) in three sublines of the CC531 colon adenocarcinoma cell line in vitro. , 1994, Cancer research.

[174]  L. Pendyala,et al.  In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. , 1993, Cancer research.

[175]  J. Reedijk,et al.  Reaction of mer-trichloro (diethylenetriamine)platmum(IV) chloride, (mer-[Pt(dien)Cl3]Cl), with purine nucleosides and nucleotides results in formation of platinum(II) as well as platinum(IV) complexes , 1993 .

[176]  A. Hart,et al.  Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. , 1993, Cancer research.

[177]  R. Perez-soler,et al.  Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. , 1993, Cancer research.

[178]  A. Khokhar,et al.  Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. , 1993, Cancer research.

[179]  B. Van Houten,et al.  Ligand effects on platinum binding to DNA. A comparison of DNA binding properties for cis- and trans-[PtCl2(amine)2] (amine = NH3, pyridine). , 1993, Biochemistry.

[180]  G. Bérubé,et al.  Synthesis and preliminary in vitro biological activity of non-steroidal cytotoxic estrogens designed for the treatment of breast cancer , 1993 .

[181]  C. Job,et al.  Spectrum of DNA--platinum adduct recognition by prokaryotic and eukaryotic DNA-dependent RNA polymerases. , 1993, Biochemistry.

[182]  L. Kèlland,et al.  In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. , 1993, British Journal of Cancer.

[183]  W. E. Lindup,et al.  Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. , 1993, Biochemical pharmacology.

[184]  S. Howell,et al.  Cellular accumulation of the anticancer agent cisplatin: a review. , 1993, British Journal of Cancer.

[185]  L. Kèlland,et al.  Antitumor-activity of orally-administered ammine amine platinum (iv) dicarboxylate complexes against a panel of human ovarian-carcinoma xenografts. , 1993, International journal of oncology.

[186]  L. Kèlland,et al.  Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. , 1993, Cancer research.

[187]  P. Sadler,et al.  Ring-opening reactions of the anticancer drug carboplatin : NMR characterization of cis-[Pt(NH3)2(CBDCA-O)(5'-GMP-N7) in solution , 1993 .

[188]  A. Khokhar,et al.  Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. , 1993, Anti-cancer drugs.

[189]  G. Natile,et al.  A trans-platinum complex showing higher antitumor activity than the cis congeners. , 1993, Journal of medicinal chemistry.

[190]  S. Chaney,et al.  Role of carrier ligand in platinum resistance of human carcinoma cell lines. , 1993, Cancer research.

[191]  J. Gietema,et al.  A PHASE-I STUDY OF IOBAPLATIN (D-19466) ADMINISTERED BY 72H CONTINUOUS INFUSION , 1993 .

[192]  N. Mulder,et al.  A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days. , 1993, British Journal of Cancer.

[193]  J. C. Jones,et al.  Repair of individual DNA strands in the hamster dihydrofolate reductase gene after treatment with ultraviolet light, alkylating agents, and cisplatin. , 1993, The Journal of biological chemistry.

[194]  G. Meersma,et al.  Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. , 1992, Cancer research.

[195]  R. Perez-soler,et al.  Lipophilic cisplatin analogues entrapped in liposomes: role of intraliposomal drug activation in biological activity. , 1992, Cancer research.

[196]  V. Bohr,et al.  Repair of mitochondrial DNA after various types of DNA damage in Chinese hamster ovary cells. , 1992, Carcinogenesis.

[197]  A. Juhász,et al.  Short-chain analogs of luteinizing hormone-releasing hormone containing cytotoxic moieties. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[198]  P. O'Connor,et al.  Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines , 1992, Molecular and cellular biology.

[199]  Douglas P. Kalinowski,et al.  Analysis of DNA damage and repair in murine leukemia L1210 cells using a quantitative polymerase chain reaction assay , 1992, Nucleic Acids Res..

[200]  K. Comess,et al.  Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts. , 1992, Biochemistry.

[201]  S. Lippard,et al.  Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. , 1992, Science.

[202]  L. Kèlland,et al.  Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. , 1992, Cancer research.

[203]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[204]  N. Farrell,et al.  Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization, and biological activity of complexes with the planar ligands pyridine, N-methylimidazole, thiazole and quinoline. Crystal and molecular structure of trans-dichlorobis (thiazole)platinum(II) , 1992 .

[205]  V. Brabec,et al.  Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. , 1992, Nucleic acids research.

[206]  W. Kaufmann,et al.  Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. , 1991, Carcinogenesis.

[207]  W. J. Vijgh.  Clinical Pharmacokinetics of Carboplatin , 1991 .

[208]  John D. Roberts,et al.  Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. , 1991, Cancer research.

[209]  N. Knebel,et al.  2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors. , 1991, Journal of medicinal chemistry.

[210]  H. Earl,et al.  A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[211]  J. C. Jones,et al.  Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. , 1991, The Journal of biological chemistry.

[212]  K. Eguchi,et al.  Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. , 1991, Cancer research.

[213]  A. Eastman,et al.  Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. , 1991, The Journal of clinical investigation.

[214]  M. Christian,et al.  Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adducts. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[215]  R. Baan,et al.  Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. , 1990, Cancer research.

[216]  A. Eastman,et al.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. , 1990, Biochemical pharmacology.

[217]  B. Van Houten,et al.  Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues. , 1990, Biochemistry.

[218]  S. Chaney,et al.  Role of carrier ligand in platinum resistance in L1210 cells. , 1990, Cancer research.

[219]  K. Inagaki,et al.  Characterization of (1,2-cyclohexanediamine)platinum(II) isomers and their d(GpG) adducts by means of proton NMR spectroscopy. A minor structural change induced by the isomers , 1990 .

[220]  S. Lippard,et al.  Effect of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. , 1990, Biochemistry.

[221]  R. Gust,et al.  Platinum compounds with estrogen receptor affinity. , 1990, Cancer treatment reviews.

[222]  B. Keppler,et al.  Cisplatin-linked phosphonates in the treatment of the transplantable osteosarcoma in vitro and in vivo. , 1990, Cancer treatment reviews.

[223]  Christopher A. Lepre,et al.  Platinum-195 NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA , 1990 .

[224]  R. Perez-soler,et al.  Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). , 1990, Cancer research.

[225]  C. Sorenson,et al.  Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. , 1990, Journal of the National Cancer Institute.

[226]  S. Gullans,et al.  Mitochondrial injury: an early event in cisplatin toxicity to renal proximal tubules. , 1990, The American journal of physiology.

[227]  T. Tanaka,et al.  Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). , 1990, Cancer research.

[228]  S. Chaney,et al.  Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. , 1990, Biochemistry.

[229]  John D. Roberts,et al.  Interaction of novel bis(platinum) complexes with DNA. , 1989, Nucleic acids research.

[230]  N. Farrell,et al.  Cytostatic trans-platinum(II) complexes. , 1989, Journal of medicinal chemistry.

[231]  A. Schally,et al.  Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[232]  R. Ozols,et al.  Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. , 1988, Biochemical pharmacology.

[233]  C. Sorenson,et al.  Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. , 1988, Cancer research.

[234]  J. Reedijk,et al.  Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. , 1988, Cancer research.

[235]  A. Fojo,et al.  Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. , 1988, Cancer research.

[236]  D. Hamer,et al.  Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.

[237]  R. Perez-soler,et al.  Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles. , 1988, Cancer research.

[238]  C. Sorenson,et al.  Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. , 1988, Cancer research.

[239]  N. Farrell,et al.  Bis(platinum) complexes containing two platinum cis-diammine units. Synthesis and initial DNA-binding studies , 1988 .

[240]  A. Eastman,et al.  Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). , 1988, Biochemistry.

[241]  B. Hill,et al.  Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. , 1988, Cancer research.

[242]  R. Perez-soler,et al.  Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles. , 1987, Cancer research.

[243]  F. Friedlos,et al.  Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cis-diamminedichloroplatinum(II) on DNA. , 1987, Cancer research.

[244]  A. Eastman,et al.  Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione. , 1987, Biochemistry.

[245]  P. Dedon,et al.  Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. , 1987, Biochemical pharmacology.

[246]  C. Wolf,et al.  Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient , 1987, International journal of cancer.

[247]  A. V. van Oosterom,et al.  cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). , 1987, Cancer research.

[248]  A. Eastman,et al.  Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. , 1987, Cancer research.

[249]  J. Vollano,et al.  Comparative antitumor studies on platinum(II) and platinum(IV) complexes containing 1,2-diaminocyclohexane. , 1987, Journal of medicinal chemistry.

[250]  R C Young,et al.  Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. , 1987, Cancer research.

[251]  V. Gattone,et al.  Mitochondrial alterations in cisplatin-induced acute renal failure. , 1986, The American journal of physiology.

[252]  L. Demers,et al.  Aortic pressure as a determinant of cardiac protein degradation. , 1986, The American journal of physiology.

[253]  D. Lydall,et al.  Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. , 1986, Cancer research.

[254]  S. Lippard,et al.  In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. , 1985, Biochemistry.

[255]  P. Lohman,et al.  Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II). , 1985, Cancer research.

[256]  P. Lohman,et al.  Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. , 1985, Biochemistry.

[257]  A. P. Simmonds,et al.  Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay. , 1984, British Journal of Cancer.

[258]  H. Pinedo,et al.  Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin. , 1984, Cancer treatment reports.

[259]  A. Pasini,et al.  Enantiomeric cisplatin analogues: an investigation on their activity towards tumors in mice , 1984 .

[260]  L. Thompson,et al.  Defective removal of DNA cross-links in a repair-deficient mutant of Chinese hamster cells. , 1982, Cancer research.

[261]  T. Tashiro,et al.  Relation of conformation to antitumor activity of platinum(II) complexes of 1,2-cyclohexanediamine and 2-(aminomethyl)cyclohexylamine isomers against leukemia P388. , 1981, Journal of medicinal chemistry.

[262]  T. Tashiro,et al.  Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. , 1980, Gan.

[263]  J. O’Neill,et al.  Mutagenicity, cytotoxicity, and DNA binding of platinum(II)-chloroammines in Chinese hamster ovary cells. , 1980, Cancer research.

[264]  J. J. Roberts,et al.  The interaction of antitumour platinum compounds with cellular DNA in cultured cells and animal tissues: relationship to DNA cellular repair processes , 1978 .

[265]  K. Inagaki,et al.  Antitumor activity of 1,2-diaminocyclohexane--platinum complexes against sarcoma-180 ascites form. , 1978, Journal of medicinal chemistry.

[266]  C. Rawlings,et al.  Increased sensitivity of UV-repair-deficient human cells to DNA bound platinum products which unlike thymine dimers are not recognized by an endonuclease extracted from Micrococcus luteus. , 1978, Mutation research.

[267]  B. Rosenberg.  Platinum complexes for the treatment of cancer , 1978 .

[268]  T. Tashiro,et al.  Antitumor activity of water-soluble platinum(II) complexes of 1,2-cyclohexanediamine isomers. , 1978, Gan.

[269]  J. Burchenal,et al.  Lack of cross-resistance between certain platinum coordination compounds in mouse leukemia. , 1977, Cancer research.

[270]  R. Golbey,et al.  High dose Cis‐platinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis , 1977, Cancer.

[271]  T. A. Connors,et al.  New platinum complexes with anti-tumour activity. , 1972, Chemico-biological interactions.

[272]  J. Trosko,et al.  Platinum Compounds: a New Class of Potent Antitumour Agents , 1969, Nature.

[273]  A. Khokhar,et al.  Differential antitumor activity and toxicity of isomeric 1,2-diaminocyclohexane platinum (II) complexes , 2005, Journal of Cancer Research and Clinical Oncology.

[274]  B. Keppler,et al.  Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? , 2005, Journal of Cancer Research and Clinical Oncology.

[275]  R. Voegeli,et al.  D-19466, a new cyclobutane-platinum complex with antitumor activity , 2005, Journal of Cancer Research and Clinical Oncology.

[276]  E. Gamelin,et al.  Long-term pharmacokinetic behavior of platinum after cisplatin administration , 2004, Cancer Chemotherapy and Pharmacology.

[277]  R. Perez-soler,et al.  Pharmacokinetics of liposome-entrappedcis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat , 2004, Cancer Chemotherapy and Pharmacology.

[278]  M. Espié,et al.  Phase I study of oxaliplatin in patients with advanced cancer , 2004, Cancer Chemotherapy and Pharmacology.

[279]  R. Perez-soler,et al.  Lipophilic platinum complexes entrapped in liposomes: improved stability and preserved antitumor activity with complexes containing linear alkyl carboxylato leaving groups , 2004, Cancer Chemotherapy and Pharmacology.

[280]  K. Eguchi,et al.  Pharmacokinetics of (glycolato-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin , 2004, Cancer Chemotherapy and Pharmacology.

[281]  C. Bokemeyer,et al.  Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[282]  T. Miki,et al.  Phase II study ofcis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract , 2004, Cancer Chemotherapy and Pharmacology.

[283]  B. Sikic,et al.  Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion , 2004, Cancer Chemotherapy and Pharmacology.

[284]  N. Farrell.  Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents , 2000 .

[285]  M. Highley,et al.  Clinical Experience with Cisplatin and Carboplatin , 2000 .

[286]  J. Reedijk,et al.  Glutathione readily replaces the thioether on platinum in the reaction with [Pt(dien)(GSMe)]2+ (GSMe = S-methylated glutathione); a model study for cisplatin–protein interactions , 2000 .

[287]  K. Eguchi,et al.  Combination of nedaplatin and vindesine for treatment of relapsed or refractory non-small-cell lung cancer , 2000, Cancer Chemotherapy and Pharmacology.

[288]  H. Choy,et al.  Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy , 2000, Cancer Chemotherapy and Pharmacology.

[289]  S. Berners‐Price,et al.  The Chemistry of Cisplatin in Aqueous Solution , 2000 .

[290]  F. Lévi,et al.  Oxaliplatin: pharmacokinetics and chronopharmacological aspects. , 2000, Clinical pharmacokinetics.

[291]  S. Wyrick,et al.  Biotransformations of oxaliplatin in rat blood in vitro , 1999, Journal of biochemical and molecular toxicology.

[292]  S. Wyrick,et al.  Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats , 1999, Cancer Chemotherapy and Pharmacology.

[293]  S. Wyrick,et al.  Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model , 1999, Cancer Chemotherapy and Pharmacology.

[294]  M. Ratain,et al.  A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days , 1999, Cancer Chemotherapy and Pharmacology.

[295]  A. Adjei,et al.  Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[296]  E. Raymond,et al.  Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.

[297]  G. Natile,et al.  trans-Platinum Compounds in Cancer Therapy: A Largely Unexplored Strategy for Identifying Novel Antitumor Platinum Drugs , 1999 .

[298]  S. Lippard,et al.  Anticancer Activity of Cisplatin and Related Complexes , 1999 .

[299]  M. Newman,et al.  Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice , 1999, Cancer Chemotherapy and Pharmacology.

[300]  D. Zamble.  The responses of cellular proteins to cisplatin-damaged DNA , 1999 .

[301]  L. Kèlland,et al.  Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). , 1998, Anti-cancer drug design.

[302]  L. Kèlland,et al.  In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. , 1998, British Journal of Cancer.

[303]  S. Wyrick,et al.  Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. , 1998, Oncology research.

[304]  T. Hambley,et al.  Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. , 1997, British Journal of Cancer.

[305]  L. Anderson,et al.  Transplacental cisplatin exposure induces persistent fetal mitochondrial and genomic DNA damage in patas monkeys. , 1997, Reproductive toxicology.

[306]  L. Anderson,et al.  Elevated mitochondrial cisplatin-DNA adduct levels in rat tissues after transplacental cisplatin exposure. , 1997, Carcinogenesis.

[307]  W. Rose.  Combination chemotherapy involving orally administered etoposide and JM-216 in murine tumor models , 1997, Cancer Chemotherapy and Pharmacology.

[308]  N. Farrell.  Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. , 1996, Metal ions in biological systems.

[309]  L. Kèlland,et al.  Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours. , 1996, Anticancer research.

[310]  L. Kèlland,et al.  Biotransformation of the platinum drug JM216 following oral administration to cancer patients , 1996, Cancer Chemotherapy and Pharmacology.

[311]  V. Brabec,et al.  DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2]. , 1996, Nucleic acids research.

[312]  R. Gust,et al.  Reduction of the Estrogenic Side Effects of the Mammary Tumor‐Inhibiting Drug [1,2‐Bis(2,6‐dichloro‐4‐hydroxyphenyl)‐ethylenediamine]dichloroplatinum(II) by Variation of Ring Substituents , 1995, Archiv der Pharmazie.

[313]  P. Sadler,et al.  L-Methionine increases the rate of reaction of 5′-guanosine monophosphate with the anticancer drug cisplatin: mixed-ligand adducts and reversible methionine binding , 1995 .

[314]  L. Kèlland,et al.  Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin. , 1995, European journal of cancer.

[315]  T. Hambley,et al.  The Influence of the Axial Ligands of a Series of Platinum(IV) Anti-Cancer Complexes on Their Reduction to Platinum(II) and Reaction With DNA , 1995 .

[316]  A. Khokhar,et al.  Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes. , 1994, Anti-cancer drug design.

[317]  B. Hill,et al.  Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. , 1994, European journal of cancer.

[318]  R. Gust,et al.  Synthesis and evaluation of the anti-mammary tumor activity and of the estrogenic side effects of [1,2-bis(2,6-dihalo-3-hydroxyphenyl)ethylenediamine]platinum(II) complexes , 1993 .

[319]  B. Keppler.  Metal complexes in cancer chemotherapy , 1993 .

[320]  L. Kèlland,et al.  New Platinum Drugs , 1993 .

[321]  E. Angerer.  Platinum complexes with specific activity against hormone-dependent tumors , 1993 .

[322]  H. Warenius,et al.  Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. , 1992, International journal of radiation oncology, biology, physics.

[323]  R. Perez-soler,et al.  Chemical and biological studies on a series of lipid-soluble (trans-(R,R)- and -(S,S)-1,2-diaminocyclohexane)platinum(II) complexes incorporated in liposomes. , 1991, Journal of medicinal chemistry.

[324]  A. Eastman,et al.  The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diaminocyclohexaneplatinum complexes and ultraviolet irradiation. , 1991, Mutation research.

[325]  T. Murata,et al.  Preferential binding of cisplatin to mitochondrial DNA and suppression of ATP generation in human malignant melanoma cells. , 1990, Biochemistry international.

[326]  S. Howell,et al.  Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. , 1990, Cancer communications.

[327]  J. Misset,et al.  Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[328]  A. Eastman,et al.  Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. , 1989, Chemico-biological interactions.

[329]  Martin R. Schneider,et al.  Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum (II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma. , 1988, Journal of medicinal chemistry.

[330]  A. Kraker,et al.  Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. , 1988, Cancer research.

[331]  Presnov Ma,et al.  Cycloplatam and oxoplatin--the new antitumor platinum compounds of the second generation. , 1988 .

[332]  F. Friedlos,et al.  Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts. , 1987, Cancer research.

[333]  J. Misset,et al.  A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). , 1986, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[334]  K. Inagaki,et al.  Differences in binding of (1,2-cyclohexanediamine)platinum(II) isomers with d(GpG) , 1986 .

[335]  J. Roberts.  Antitumor Platinum Compounds , 1979 .

[336]  J. Hoeschele,et al.  Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum (II) complexes , 1973 .